Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Park S-H, Kukushkin Y, Gupta R, Chen T, Konagai A, Hipp MS, et al
TB-500 is best viewed as a broad-acting peptide that supports systemic healing, angiogenesis, and muscle recovery, while BPC-157 is more localized in action, excelling in tendon, ligament, and gastrointestinal repair
WADA Prohibition The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes: Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments) Prohibited at all times (both in-competition and out-of-competition) No Therapeutic Use Exemptions (TUEs) available Detection methods developed and implemented in anti-doping laboratories worldwide WADAs 2013 statement clarified that AOD-9604 is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world. Research Classification: AOD-9604 is available only for laboratory research use
We also handle framework agreements over 6 to 12 months
Lifetime prevalence in the USA is 28.8 % of all adults (National Institute of Mental Health 2016c)
Synthetic peptides are engineered to improve bioavailability, target selectivity, and half-life, often surpassing the pharmacokinetic limitations of natural peptides. Vlieghe et al., Drug Discovery Today Do Natural and Synthetic Peptides Have Different Clearance Times
US$ 23.70
US$ 27.95
US$ 24.69
US$ 24.81